PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19345745-10	2009	These effects were reversed by blocking JNK or p38 MAPK using pharmacological inhibitors (SP 600125, and SB 203580).	SB 203580	105-114	mitogen-activated protein kinase 8	Rattus norvegicus	40-43	
11514286-8	2001	These data suggest that SB-203580 likely attenuates IPC via the inhibition of kinases other than p38, which may include JNK.	SB 203580	24-33	mitogen-activated protein kinase 8	Rattus norvegicus	120-123	
17434686-10	2007	Moreover, growth of neurites induced by octanoic acid was potently inhibited by treatment of cells with the p38 MAPK inhibitor SB203580 and the ERK kinase inhibitor PD98059 but not inhibited and only slightly inhibited by the JNK inhibitor SP600125 and the PI3K inhibitor wortmannin, respectively.	SB 203580	127-135	mitogen-activated protein kinase 8	Rattus norvegicus	226-229	
15979653-4	2005	SB203580 and JNK inhibitor I, specific inhibitors of P38 and JNK, inhibited TNF-alpha production in KCs but PD98059, an inhibitor of the ERK pathway, did not affect TNF-alpha production by KCs.	SB 203580	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	61-64	
12641726-8	2003	Here, we also found that activation of p38 MAPK/JNK is accompanied by cytochrome c release from the mitochondria and caspase activation (which can be inhibited by SB203580), suggesting that anandamide triggers a mitochondrial dependent apoptotic pathway.	SB 203580	163-171	mitogen-activated protein kinase 8	Rattus norvegicus	48-51	
16283237-6	2005	MATERIALS AND METHODS: The MAPKs ERK, p38 and JNK were inhibited by SB203580, PD98059 or Tat-JNK binding domain or by cells overexpressing the JNK binding domain.	SB 203580	68-76	mitogen-activated protein kinase 8	Rattus norvegicus	46-49	
15608389-6	2004	Blocking studies using pretreatment of the inhibitor of each pathway revealed that p38 MAPK cascade may be important for aldosterone-mediated CTGF upregulation as evidenced by the blocking of CTGF induction by SB203580 (p38 MAPK inhibitor), but not by PD098059 (ERK1/2 inhibitor) and JNK inhibitor I. Interestingly, JNK inhibitor I and PD098059 decreased the basal level of CTGF expression.	SB 203580	210-218	mitogen-activated protein kinase 8	Rattus norvegicus	284-287	
15608389-6	2004	Blocking studies using pretreatment of the inhibitor of each pathway revealed that p38 MAPK cascade may be important for aldosterone-mediated CTGF upregulation as evidenced by the blocking of CTGF induction by SB203580 (p38 MAPK inhibitor), but not by PD098059 (ERK1/2 inhibitor) and JNK inhibitor I. Interestingly, JNK inhibitor I and PD098059 decreased the basal level of CTGF expression.	SB 203580	210-218	mitogen-activated protein kinase 8	Rattus norvegicus	316-319	
12969270-5	2003	TAK1-induced iNOS-Luc activity was substantially inhibited by pharmacological inhibitors of the known downstream kinases, p38 MAPK and JNK (SB203580 and SP620125), and was almost completely blocked by co-expression of a phosphorylation mutant of IkappaB.	SB 203580	140-148	mitogen-activated protein kinase 8	Rattus norvegicus	135-138	
11446828-8	2001	Blocking the p38 or JNK signaling pathways using the inhibitors SB203580 or CEP-1347 protected cerebellar neurons against arsenite-induced apoptosis.	SB 203580	64-72	mitogen-activated protein kinase 8	Rattus norvegicus	20-23	
10807932-8	2000	SB203580 did not affect IL-1beta-induced ERK activation, yet enhanced IL-1beta-induced JNK activation approximately 2-fold.	SB 203580	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	87-90	
35155684-9	2022	The AGE-induced upregulation of osteoblast proteins (RUNX2 and OPG) was suppressed by treatment with a p38MAPK inhibitor (SB203580) or JNK inhibitor (SP600125), but not by treatment with an ERK inhibitor (PD98059), which indicated that AGE-induced osteoblast differentiation from EPCs may be mediated by p38MAPK and JNK signaling, but not by ERK signaling.	SB 203580	122-130	mitogen-activated protein kinase 8	Rattus norvegicus	316-319	
10230866-10	1999	SB203580 inhibited not only p38 but also JNK activities extracted from granule neurons.	SB 203580	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	41-44	
30216497-7	2018	Further studies demonstrated that injection of the JAK2 antagonist AG490 or JNK antagonist SP600125 into the RN 30 min prior to the administration of rrIL-1beta could completely prevent IL-1beta-evoked tactile allodynia, while injection of the ERK antagonist PD98059, p38 MAPK antagonist SB203580, or NF-kappaB antagonist PDTC did not affect IL-1beta-evoked tactile allodynia.	SB 203580	288-296	mitogen-activated protein kinase 8	Rattus norvegicus	76-79	
32688140-12	2020	We treated H9c2 cells with LY317615, SP600125, and SB203580, inhibitors of PKCalpha, JNK, and P38, respectively, thereby resulting in a substantial decrease in hypertrophy, fibrosis, and apoptosis.	SB 203580	51-59	mitogen-activated protein kinase 8	Rattus norvegicus	85-88	
28250268-9	2017	Treatment of the cells with specific inhibitors including SB203580, SP600125, and LY294002 suppressed the luteolin-induced HO-1 expression, suggesting the involvement of p38 MAPK, JNK, and Akt in HO-1 induction.	SB 203580	58-66	mitogen-activated protein kinase 8	Rattus norvegicus	180-183	
29802528-8	2018	SP600125 and SB203580, which is the JNK/P38 pathway inhibitors has the same protective effect as ATRA.	SB 203580	13-21	mitogen-activated protein kinase 8	Rattus norvegicus	36-39	
26126628-6	2015	PD98059, SB203580, and SP600125 were used to inhibit ERK1/2, p38 MAPK, and JNK signaling pathways, respectively, and anisomycin was used to activate JNK pathway.	SB 203580	9-17	mitogen-activated protein kinase 8	Rattus norvegicus	75-78	
26176363-7	2015	Furthermore, inhibition of JNK and p38 mitogen-activated protein kinases (MAPKs) were observed after mGluR4 activation, and as paralleling control, JNK-specific inhibitor SP600125 and p38-specific inhibitor SB203580 significantly rescued the H2O2-mediated NSC apoptosis and cleavage of procaspase-3.	SB 203580	207-215	mitogen-activated protein kinase 8	Rattus norvegicus	27-30	
26968558-8	2016	Similarly, high glucose up-regulated ACE expression in NRK-52E cells, which was blocked by the p38 MAPK inhibitor SB203580, but not the extracellular signal-regulated kinase (ERK) inhibitor FR180204 or the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	SB 203580	114-122	mitogen-activated protein kinase 8	Rattus norvegicus	231-234	
24651933-7	2014	The increased phosphorylation of p38 and JNK induced by OGD was decreased under the treatment of curcumin, whereas the p38 inhibitor, SB203580, significantly inhibited OGD-induced IL-1beta production, but the JNK inhibitor, SP600125, failed to do so.	SB 203580	134-142	mitogen-activated protein kinase 8	Rattus norvegicus	209-212	
24118820-7	2014	These injuries were significantly attenuated by the pre-treatment of cells with either naringin or SB203580 (a selective inhibitor of p38 MAPK) or U0126 (a selective inhibitor of extracellular signal regulated kinase 1/2, ERK1/2) or SP600125 (a selective inhibitor of c-jun N-termanal kinase, JNK) before exposure to HG, respectively.	SB 203580	99-107	mitogen-activated protein kinase 8	Rattus norvegicus	293-296	
23258322-7	2012	However, ERK inhibitor PD98059 (20 mumol/L) or JNK inhibitor SP600125 (20 mumol/L) did not influence caspase-3 activity; (3) Pretreatment with SB203580 significantly reduced the number of NMDA-induced TUNEL-positive cells by 33.10% (P < 0.05).	SB 203580	143-151	mitogen-activated protein kinase 8	Rattus norvegicus	47-50	
24406296-9	2014	In addition, inhibiting the JNK and p38 pathways by SP600125 and SB203580 respectively attenuated the LPS-induced apoptosis and regulated the expression of apoptosis-related proteins Bcl-2 and Bax.	SB 203580	65-73	mitogen-activated protein kinase 8	Rattus norvegicus	28-31	
22452662-8	2013	In vitro, heat stress caused damage and apoptosis in IEC-6 cells; inhibition of ERK1/2 activation (by U0126) exacerbated these effects, which were attenuated by inhibition of JNK (by SP600125) and p38 (by SB203580) activation.	SB 203580	205-213	mitogen-activated protein kinase 8	Rattus norvegicus	175-178	
22410671-6	2012	Additionally, the c-jun N-terminal kinase (JNK) inhibitor (SP600125) dose-dependently inhibited LPS-induced CCL2 upregulation, whereas the MAPK kinase (MEK) inhibitor (PD98059) only had a mild effect and the p38 MAPK inhibitor (SB203580) had no effect.	SB 203580	228-236	mitogen-activated protein kinase 8	Rattus norvegicus	43-46	
21468599-6	2011	p38, ERK1/2 and JNK were respectively inhibited with the specific inhibitors SB203580, PD98059 and SP600125.	SB 203580	77-85	mitogen-activated protein kinase 8	Rattus norvegicus	16-19